Ulm, Germany
NVision Quantum Technologies, founded in 2015 and headquartered in Germany, is at the forefront of integrating quantum technology into medical imaging. The company's slogan, "Leveraging quantum technology to enable imaging of cell metabolism via hyperpolarized MRI," encapsulates their ambitious goal to revolutionize the domain of medical imaging.
Their flagship innovation, the POLARIS device, stands out by providing fast, straightforward, and scalable imaging of cellular metabolism. This hyperpolarization technology facilitates significant advancements in early detection, treatment assessment, and risk profiling, proving beneficial in fields such as oncology, cardiology, and neurology.
In their most recent round of funding in May 2026, NVision secured a substantial $38 million through debt financing. This investment round saw participation from notable investors, including Playground Global, Entrée Capital, Matterwave Ventures, CDP Venture Capital SGR, and Abbott, highlighting substantial confidence in their innovative solutions and growth potential.
